Full-Time

Medical Science Liaison

Msl, Prenatal

Confirmed live in the last 24 hours

BillionToOne

BillionToOne

201-500 employees

Molecular diagnostics for prenatal and oncology testing

Compensation Overview

$132.6k - $153kAnnually

+ Equity Options + Corporate Bonus Program

Mid, Senior

Remote in USA

Candidate must reside in the Northeast Region, Texas, or Florida and ability to travel up to 70% nationwide.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Requirements
  • Master’s degree in Genetic Counseling
  • Board certified ABGC or ABMG
  • 3-5 years of prenatal clinical and/or industry experience in related field required
  • Expertise in discussing scientific content and context to multiple audiences
  • Excellent communication, presentation and interpersonal skills
  • Ability to travel (up to 70%) – percentage varies with geography
Responsibilities
  • Serve as a key liaison to health care providers (HCPs)
  • Serve as a key member of the BillionToOne Medical Affairs team
  • Develop relationships by engaging in scientific exchange with medical and scientific partners
  • Support commercial team by providing impactful information that enhances the value and proper use of BillionToOne products
  • Respond to HCP customer inquiries to provide focused and balanced clinical and scientific information that supports the appropriate use of BillionToOne’s prenatal products
  • Provide education regarding the clinical differentiation of BillionToOne's products and services
  • Contribute to development of provider and patient educational products
  • Adhere to internal standard processes and comply with regulatory and compliance requirements

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair level, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne's business model centers on providing these diagnostic services directly to healthcare providers, generating revenue through the sale of testing services that inform treatment decisions. The goal of BillionToOne is to enhance the accuracy, efficiency, and accessibility of molecular testing, driven by a commitment to growth, equality, and teamwork in making a positive impact on healthcare.

Company Size

201-500

Company Stage

Series D

Total Funding

$380.2M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne achieved over 100% revenue growth in 2024, reaching $153 million.
  • Their prenatal testing business captured 15% of the U.S. market share.
  • The company is expanding with a new facility in Austin, creating 1,000 jobs.

What critics are saying

  • Increased competition in prenatal and oncology testing markets threatens market share.
  • Rapid technological advancements require continuous R&D investment, straining resources.
  • Expansion into new facilities may pose operational challenges and increase costs.

What makes BillionToOne unique

  • BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
  • Their non-invasive prenatal test offers 100% accuracy for fetal RhD status.
  • They replace risky amniocentesis with safe, affordable blood tests in developing countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

1%
PR Newswire
Feb 27th, 2025
Billiontoone'S Pioneering Study Demonstrates 100% Accuracy For Non-Invasive Fetal Rhd Detection In Us Population

Peer reviewed research published in Green Journal shows BillionToOne's NGS technology excels in testing diverse US populationsMENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today the groundbreaking results from a recent large US-based clinical study demonstrating 100% accuracy in its non-invasive prenatal test (NIPT) for fetal RhD status. This is BillionToOne's third peer reviewed study of its fetal antigen assay, and the second published in The Journal of Obstetrics and Gynecology, the official journal of the American College of Obstetricians and Gynecologists (ACOG), also known as "The Green Journal," which showcases the accuracy and clinical validity of BillionToOne's fetal RhD NIPT.Approximately 15% of pregnant individuals in the US are RhD-negative. However, in ~40% of these pregnancies, the fetus is also RhD-negative, making RhoGAM administration unnecessary. To date, BillionToOne has conducted RhD testing on 469 participants through clinical validation studies, while providing over 150,000 commercial RhD tests to patients nationwide.This study demonstrates that BillionToOne's proprietary next-generation sequencing (NGS) with Quantitative Counting Template™ (QCT™) technology provides conclusive results with 100% accuracy. BillionToOne's study included all samples, including difficult to identify variants such as RHDѰ and RHD-C-DE, which are often excluded in other studies; therefore, it reflected true clinical performance

PR Newswire
Jan 28th, 2025
Billiontoone Reports Over 100% Growth In Revenue Year-Over-Year

Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne

Webrazzi
Dec 30th, 2024
2024 Yılında En Çok Yatırım Alan 10 Yerli Girişim

2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu

PR Newswire
Dec 23rd, 2024
Billiontoone To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2025.BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years.This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows:Location: Mission Bay (32nd Floor) at The WestinDate: Tuesday, January 14, 2025Time: 2:30-2:55 pm PTA webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone

BillionToOne
Nov 20th, 2024
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards

BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards.